Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade with Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial. Marta Trigo-Rodriguez , Sheila Carcel , Ana Navas , Reinaldo Espindola-Gomez , Jose Carlos Garrido-Gracia , Maria Angeles Esteban Moreno , Rafael Leon-Lopez , Pedro Maria Martinez Perez-Crespo , Eduardo Aguilar Alonso , David Vinuesa , Alberto Romero-Palacios , Ines Perez-Camacho , Belen Gutierrez-Gutierrez , Francisco Javier Martinez-Marcos , Concepcion Fernandez-Roldan , Eva Leon , Alexandra Aceituno Cano , Juan E. Corzo-Delgado , Elena Perez-Nadales , Cristina Riazzo , Carmen de la Fuente , Aurora Jurado , Julian Torre-Cisneros , Nicolas Merchante SSRN Electronic Journal（2022）
Key words
COVID-19, IL-6, IP-10, SARS-CoV-2, sarilumab, tocilizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
